340 related articles for article (PubMed ID: 35900317)
21. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
22. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Mi JQ; Zhao W; Jing H; Fu W; Hu J; Chen L; Zhang Y; Yao D; Chen D; Schecter JM; Yang F; Tian X; Sun H; Zhuang SH; Ren J; Fan X; Jin J; Niu T; Chen SJ
J Clin Oncol; 2023 Feb; 41(6):1275-1284. PubMed ID: 36269898
[TBL] [Abstract][Full Text] [Related]
23. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
[TBL] [Abstract][Full Text] [Related]
24. Current state and next-generation CAR-T cells in multiple myeloma.
Manier S; Ingegnere T; Escure G; Prodhomme C; Nudel M; Mitra S; Facon T
Blood Rev; 2022 Jul; 54():100929. PubMed ID: 35131139
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
Zhao G; Wei R; Feng L; Wu Y; He F; Xiao M; Cheng Z
Cancer Immunol Immunother; 2022 Jan; 71(1):39-44. PubMed ID: 34003300
[TBL] [Abstract][Full Text] [Related]
26. Sequence not salvage.
Sborov DW; Fortuna GG; Hayden PJ
Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
[TBL] [Abstract][Full Text] [Related]
27. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Qu X; An G; Sui W; Wang T; Zhang X; Yang J; Zhang Y; Zhang L; Zhu D; Huang J; Zhu S; Yao X; Li J; Zheng C; Zhu K; Wei Y; Lv X; Lan L; Yao Y; Zhou D; Lu P; Qiu L; Li J
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100310
[TBL] [Abstract][Full Text] [Related]
29. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
30. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
31. [Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA].
Sun Q; Qi YK; Qi KM; Yan ZL; Cheng H; Chen W; Zhu F; Sang W; Li DP; Cao J; Shi M; Li ZY; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):832-837. PubMed ID: 38049335
[No Abstract] [Full Text] [Related]
32. Toxicity of CAR T-Cell Therapy for Multiple Myeloma.
Afrough A; Abraham PR; Turer L; Kaur G; Sannareddy A; Hansen DK; Anderson LD
Acta Haematol; 2024 May; ():1-15. PubMed ID: 38718775
[TBL] [Abstract][Full Text] [Related]
33. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Fischer L; Grieb N; Born P; Weiss R; Seiffert S; Boldt A; Fricke S; Franz P; Heyn S; Kubasch AS; Baber R; Weidner H; Wang SY; Bach E; Hoffmann S; Ussmann J; Kirchberg J; Hell S; Schwind S; Metzeler KH; Herling M; Jentzsch M; Franke GN; Sack U; Reiche K; Köhl U; Platzbecker U; Vucinic V; Merz M
Leukemia; 2024 Feb; 38(2):372-382. PubMed ID: 38184754
[TBL] [Abstract][Full Text] [Related]
34. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.
Cornell RF; Bishop MR; Kumar S; Giralt SA; Nooka AK; Larson SM; Locke FL; Raje NS; Lei L; Dong J; Le Gall JB; Rossi JM; Orlowski RZ
Am J Cancer Res; 2021; 11(6):3285-3293. PubMed ID: 34249462
[TBL] [Abstract][Full Text] [Related]
35. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.
Ouyang W; Jin SW; Xu N; Liu WY; Zhao H; Zhang L; Kang L; Tao Y; Liu Y; Wang Y; Wang J; Liu F; Yu L; Liu Z; Mi JQ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38589248
[TBL] [Abstract][Full Text] [Related]
36. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
Ri M; Suzuki K; Ishida T; Kuroda J; Tsukamoto T; Teshima T; Goto H; Jackson CC; Sun H; Pacaud L; Fujikawa E; Yeh TM; Hatayama T; Aida K; Sunagawa Y; Iida S
Cancer Sci; 2022 Dec; 113(12):4267-4276. PubMed ID: 36052883
[TBL] [Abstract][Full Text] [Related]
37. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H
Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.
Xu H; Guan C; Xu P; Zhou D; Xu Y; Chen B; Bai H
Front Oncol; 2024; 14():1355643. PubMed ID: 38651157
[TBL] [Abstract][Full Text] [Related]
39. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
Goto H
Rinsho Ketsueki; 2022; 63(6):580-588. PubMed ID: 35831191
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
